## **Core Concept**
Pentostatin, also known as deoxycoformycin, is a potent inhibitor of adenosine deaminase (ADA), an enzyme crucial for purine metabolism. This action is particularly significant in the treatment of certain types of leukemia. By inhibiting ADA, pentostatin leads to the accumulation of deoxyadenosine triphosphate (dATP), which is toxic to lymphocytes.

## **Why the Correct Answer is Right**
Pentostatin exerts its therapeutic effect by specifically inhibiting **adenosine deaminase (ADA)**, an enzyme that normally breaks down adenosine and deoxyadenosine. In the absence of ADA activity, these compounds accumulate, particularly dATP, which causes cell death, especially in lymphocytes. This mechanism is exploited in the treatment of hairy cell leukemia and some T-cell malignancies.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because pentostatin's mechanism does not primarily involve the inhibition of purine synthesis. While it does affect purine metabolism, its direct action is on the breakdown of purine nucleosides.
- **Option B:** This option is incorrect as pentostatin does not act by inhibiting DNA polymerase. Its therapeutic effect is related to the accumulation of toxic metabolites due to ADA inhibition, not interference with DNA synthesis.
- **Option C:** Although not listed as an option, it's essential to note that the correct mechanism involves ADA inhibition. If an option suggested another enzyme or pathway not directly related to ADA or purine metabolism, it would be incorrect for the same reasons.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that pentostatin is particularly effective in treating **hairy cell leukemia**, a type of cancer characterized by an accumulation of abnormal B lymphocytes in the bone marrow, spleen, and blood. Its use has significantly improved the outcomes for patients with this disease.

## **Correct Answer:** . adenosine deaminase